In vivo antimalarial and acute toxicity properties of hexane and chloroform extracts from Clausena anisata (Willd.) Benth. by Irungu, Beatrice N. et al.
Irungu et al. Afr. J. Pharmacol. Ther. 2012. 1(1): 24-29 
 
A KeSoBAP Publication ©2012. All rights reserved. 
24 
 
In vivo antimalarial and acute toxicity 
properties of hexane and chloroform extracts 
from Clausena anisata (Willd.) Benth.  
Beatrice N. Irungu a,*, Murungi J. Mbabu b, Daniel M. Kiboi a, Enock Moindi a, Johnson 
Kinyua b, and Mwirichia Romano b 
a Kenya Medical Research Institute (KEMRI), Centre for Traditional Medicine and Drug Research, Nairobi, 
Kenya 
b Institute for Biotechnology Research, Jomo Kenyatta University of Agriculture and Technology, Nairobi, 
Kenya 
_____________ 
* Corresponding author: Kenya Medical Research Institute (KEMRI), Centre for Traditional Medicine and Drug 
Research, P.O Box 54840-00200, Nairobi, Kenya; Tel: +254-20-2722541 ext 3349; Fax: +254-20-2720030; Email: 
birungu@yahoo.com 
 
Background: Drugs are an important tool for control of malaria. However, drug resistance is likely to compromise 
available antimalarial drugs with time. As a result, efforts are being directed towards discovery and development of 
novel and affordable malaria drug molecules including those from medicinal plants. 
Objectives: To investigate suppressive, curative, prophylactic and acute toxicity properties of hexane and chloroform 
extracts of Clausena anisata against murine malaria. 
Method: Activity of the extracts was tested against Plasmodium berghei ANKA strain. Extracts were administered 
orally to mice (n=5) at 500, 250 and 100 mg/kg/day. Median lethal dose was evaluated after oral administration of 
the extracts in doses ranging from 500 to 5000 mg/kg. 
Results: 500 mg/kg/day of the chloroform extract exhibited 66.1% and 73.4% parasite reduction in the prophylactic 
and suppressive tests, respectively, while the same dose of the hexane extract comparatively lower suppressive and 
prophylactic properties (56.7% and 30.7 %, respectively). In the curative test, 500 mg/kg/day of the chloroform and 
the hexane extracts resulted in mean survival times (MST) of 12.3 days and 9.3 days, respectively.  No mortality was 
observed in mice that received the hexane extract, whereas the LD50 of mice that received the chloroform extract was 
4166.7 mg/kg. These results suggest that the chloroform extract at 500 mg/kg/day had notable in vivo antimalarial 
activity and partly explain therapeutic efficacy claimed for this plant in traditional medicine. 
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1. Introduction 
Malaria is a disease caused by Plasmodium parasites 
and, though preventable and curable, is still one of the 
greatest global public health problems especially in sub-
Saharan Africa. This can be partly attributed to the 
development of resistance by malaria parasites to most 
of the established antimalarial drugs such as 
chloroquine, sulphadoxine/pyrimethamine and 
amodiaquine (Schlitzer, 2008). Currently, fixed dose 
artemisinin-based combination therapies are being 
used as first-line treatment of uncomplicated falciparum 
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malaria in endemic areas. Unfortunately, recent reports 
indicate a decline in efficacy of artemisinin derivatives 
along Thai-Cambodia border, a site historically known 
for the recurrent emergence of drug resistant malaria 
parasites (Dondorp et al, 2009; Noedl et al, 2008). New 
classes of antimalarial agents are therefore urgently 
needed given that drug resistance is likely to eventually 
compromise the efficacy of currently available 
antimalarial drugs; identification of lead antimalarial 
agents from medicinal plants could boost the search.  
Clausena anisata (Willd.) Benth is a deciduous 
shrub/tree whose leaves are aromatic. In Kenya, it is 
known locally as Mjarikali (Swahili) and Mutathi 
(Kikuyu). Traditionally, soup boiled with the roots of 
the plant was given to women after birth to cleanse the 
uterus. This soup is also highly recommended for 
headache, malaria, influenza and indigestion. Twigs are 
used as toothbrushes and are believed to cure 
toothache. Decoctions of the root are also drunk to treat 
syphilis (Kokwaro, 2009; Beentje, 1994; Gachathi, 
1989).  
Pharmacological activities associated with extracts from 
this plant include antifungal and antibacterial activity 
(Senthilkumar and Venkatesalu,  2009;  Hamza et al, 
2006; Gundidza et al, 1994), antidiabetic activity 
(Ojewole, 2002), anticonvulsant activity (Makanju, 
1983) angiotensin converting enzyme (ACE) inhibitory 
activity  (Duncan et al, 1999) and antiviral activity 
(Ayisi and Nyadedzor, 2003). Phytochemical 
investigations indicate carbazole alkaloids as the major 
component of this plant (Ito et al, 2000; Ito et al, 2009). 
Coumarins and limonoids have also been isolated 
(Ngadjui et al, 1991; Ngadjui et al, 1989; Lakshmia et al, 
1984). Pharmacological activities associated with 
carbazole alkaloids include antifungal, antibacterial and 
antiviral activities (Ito et al, 2009; Ito et al, 2000; 
Chakraborty et al, 1995). Coumarins are reported to 
have anticoagulant properties (Emerole et al, 1981). 
Steam distillation of fresh leaves yielded sweet smelling, 
brownish-yellow oil whose major component is the 
acute toxin estragole (Okunade, 1987).  
As part of our continuing efforts to identify antimalarial 
agents from medicinal plants, in vivo antimalarial 
activity and acute toxicity of C. anisata extracts were 
investigated. The plant was selected as it has been 
traditionally used to treat malaria (Kokwaro, 2009; 
Beentje, 1994).  
 
2. Material and Methods 
2.1 Plant materials 
Stem bark of C. anisata was collected from Ngong’ 
forest, Kajiado County in Kenya.  Authentication was 
carried out at the University of Nairobi Herbarium, 
School of Biological Sciences, University of Nairobi, 
where a voucher specimen was deposited (voucher 
specimen number BN/2008/1).  
 
 
2.2 Extraction 
Plant material was chopped, air-dried for a period of 
two weeks and ground using a mill. 200 g was extracted 
by repeated soaking (2 x 24 hr) successively with 
hexane and chloroform. Filtrates were separately dried 
in vacuo using a rotary evaporator yielding 1.26 g 
hexane extract (yellowish gum) and 10.03 g   
chloroform extract (dark brown gum). The solvent free 
extracts were stored at 4 °C until needed for bioassay. 
2.3 Animals 
Male Swiss mice, 8 weeks old, weighing 20±2 g were 
obtained from KEMRI animal house. They were housed 
in clearly labelled, standard Macrolon type II cages at 22 
°C and 60–70% relative humidity. They were fed on 
commercial rodent feed and water ad libitum.  
2.4 Drug (extracts) preparation 
These were freshly prepared on the day of treatment. 
Extracts were suspended in a solvent mixture consisting 
of 70% Tween-80 (d= 1.08g/ml) and 30% ethanol (d= 
0.81g/ml), then diluted 10-fold in water. Three different 
stock solutions were prepared, i.e. 10 mg/ml, 25 mg/ml 
and 50 mg/ml for 100, 250 and 500 mg/kg/day dose 
levels, respectively. 
2.5 4-day Suppressive test 
The four day test described by Peters et al (1975) was 
adapted. The animals were randomly infected 
intraperitoneally with blood containing 2 x 107 
parasitized (Plasmodium berghei ANKA) red blood cells 
contained in 0.2 ml inoculum on Day zero (D0). They 
were divided into 3 groups of 5 mice each (test, 
untreated, and positive control). 4 hours post infection, 
the test animals were orally treated with three dose 
levels, (500, 250 and 100 mg/kg/day) at a volume of 
0.01 ml/gram mouse. Positive control received 
chloroquine at 10 mg/kg/day while negative controls 
received 7% Tween-80 and 3 % ethanol in water. Drug 
administration was repeated 24, 48, and 72 hours post 
infection. On Day 4 (96 hours post infection), blood 
smears were taken by making a thin film from a tail snip 
of each mouse, fixed in methanol for about 2 minutes 
and stained with 10% Giemsa for 15 minutes. Blood 
smears were used to estimate the level of parasitaemia. 
Percentage chemosuppression (parasite reduction) was 
calculated as described by Tona et al (2001). 
2.6 Prophylactic Test 
Prophylactic properties were tested as described by 
Peters (1965).  Briefly, the test groups were treated 
orally with three dose levels 500, 250 and 100 
mg/kg/day for three consecutive days (Days 0 - 2). The 
positive control group received pyrimethamine 1.2 
mg/kg/day while the negative control group received 
7% Tween-80 and 3 % ethanol in water. On Day 3, the 
animals were infected intraperitoneally and left for a 
further four days after which blood smears were made 
and used to estimate the level of parasitaemia (%) (as 
described in Section 2.5 above). 
 
 Table 1: % Chemosuppression by C. anisata extracts in the suppressive test against P. berghei ANKA 
Type of extract 
Dosage 
(mg/kg/day) 
Average 
parasitaemia 
% 
chemosuppression 
Hexane 100 b8.7±1.2 31.4 
 250 b7.6±2.5 40.1 
 500 a5.6±1.9 56.7 
Chloroform 100 b9.2±1.5 39.8 
 250 b8.0±3.4 47.5 
 500 a4.1±1.7 73.4 
Untreated group - 15.5±4.1 - 
Chloroquine 10 mg/kg/day a0.4±0.2 96.4 
Values are expressed as mean ± SEM 
a  Significantly different from the untreated group (p<0.05) 
b Not significantly different from the untreated group  (p<0.05) 
n=5 mice per group 
Score definition >70% active: 50-69 % moderate: < 50% low 
 
Table 2: % Chemosuppression by C. anisata extracts in the prophylactic test against P. berghei ANKA 
Type of extract 
Dosage 
(mg/kg/day) 
Average 
parasitaemia 
% 
chemosuppression 
Hexane 100 b5.76±0.8 11 
 250 b4.8±2.1 11.7 
 500 b4.5±0.4 30.7 
Chloroform 100 b4.23±1.4 34.8 
 250 b3.09±0.7 52.3 
 500 a2.2±0.5 66.1 
Untreated group - 6.49±1.8 - 
Pyrimethamine 1.2 mg/kg/day a1.76±0.6 72.8 
Values are expressed as mean ± SEM 
a  Significantly different from the untreated group (p<0.05) 
b  Not significantly different from the untreated group  (p<0.05) 
n=5 mice per group 
Score definition >70% active: 50-69 % moderate: < 50% low 
 
2.7 Curative test 
This test was carried out as was described by Ryley and 
Peters (1970). All animals were infected 
intraperitoneally on Day 0 and left for 72 hours before 
commencement of treatment. Thereafter, test animals 
were orally given the extracts at three dose levels of 
500, 250 and 100 mg/kg/day for 4 consecutive days.  
Positive controls received chloroquine at 10 mg/kg/day 
while the untreated group received a solution 
consisting of 7% Tween-80 and 3% ethanol. Animals 
were observed and any death that occurred noted to 
determine the mean survival time. 
2.8 Acute Toxicity Testing and LD50 Determination 
Median lethal dose was estimated following the method 
described by Lorke, (1983). Briefly, on Day 1 mice were 
starved for 24 hours prior to drug administration. They 
were divided into two groups (test and negative 
control) of five mice each.  For each extract, a single 
dose of between 500-5000 mg/kg/day was 
administered orally on Day 2. Five different dosing 
levels were used. Negative controls received a solution 
consisting of 7% Tween-80 and 3% ethanol. The 
animals were given food and water four hours post drug 
administration. On Day 2 and 3 they were observed for 
signs of toxicity such as writhing, decreased motor 
activity, decreased body/limb tone, decreased 
respiration and death. The number of deaths that 
occurred within 48 hours was recorded.  
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Table 3: Mean Survival Time (MST) of mice treated 
with hexane and chloroform in the curative test 
Type of extract 
Dosage 
(mg/kg/day) 
Mean survival 
time in days 
Hexane 100 b7.6±0.5 
 250 b8.2±0.8 
 500 b9.3±1.9 
Chloroform 100 b9.2±1.3 
 250 b9.8±0.8 
 500 a12.3±1.7 
Untreated group  7.8±0.5 
Chloroquine 10 a21± 6.4 
Values are expressed as mean ± SEM 
a Significantly different from the untreated group (p<0.05) 
b Not significantly different from the untreated group  (p<0.05) 
n=5 mice per group 
 
 
Table 4: Effects of C. anisata extracts on uninfected 
mice 
Dose levels in 
mg/kg 
% Mortality in 48 hours 
Hexane 
extract 
Chloroform 
extract 
5000 0 (0/5) 60 (3/5) 
2811 0 (0/5) 40 (2/5) 
1581 0 (0/5) 0 (0/5) 
889.2 0 (0/5) 0 (0/5) 
500 0 (0/5) 0 (0/5) 
Values in brackets indicate the number of mice that were dead 
at the end of 48 hours 
 
2.9 Statistical Analysis 
StatView Version 5.0.1 (SAS institute Inc.) was used for 
statistical analysis. In suppressive and prophylactic 
tests Student’s t-test (Minitab Inc. software, State 
College, PA, USA) was used to evaluate the differences 
between average parasitaemia of untreated and treated 
groups.  In curative test, Student’s t-test was used to 
evaluate the differences between mean survival time of 
untreated and treated group. P-values of 0.05 or less 
were considered significant. For LD50 determination, 
probit-log analysis was used (Finney, 1964). 
2.10 Ethical considerations 
Permission to carry out this study was approved by 
KEMRI Animal Care and Use Committee. 
 
3.0 Results 
Suppressive and prophylactic activities were evaluated 
by comparing the % reduction of parasitaemia 
(chemosuppression) between the treated and untreated 
groups while the curative test compared the mean 
survival time (MST) of the treated group in comparison 
to the untreated group.  
3.1 Suppressive test 
Results are as shown in Table 1. The chloroform extract 
at 500 mg/kg/day showed 73.4% chemosuppression.  
Average parasitaemia at this dosage was significantly 
lower (p< 0.05) than that of the untreated group. The 
100 and 250 mg/kg doses showed lower suppressive 
activity, 39.8% and 47.5% respectively. The hexane 
extract at all the three dose levels had moderate to low 
chemosuppression (56.6%, 40.1% and 31.4% at 500, 
250, and 100 mg/kg/day respectively).  
However, none of the observed activities of the extracts 
was comparable to that of chloroquine (10 mg/kg/day) 
which exhibited a 96.4% chemosuppression.  
3.2 Prophylactic test  
As shown in Table 2 prophylactic activities were 
slightly lower than the suppressive activities for both 
extracts. At 500 mg/kg/day, the chloroform extract 
exhibited high (66.1%) parasite reduction; at 250 
mg/kg/day, the chloroform extract exhibited moderate 
activity at 52.3% parasite reduction. The hexane extract 
at all three dose levels showed parasite reduction of less 
than 50%.  Pyrimethamine (1.2 mg/kg/day) was used 
as a reference drug and showed a parasite reduction of 
72.8%. 
3.3 Curative test 
There was no curative property observed in mice 
treated with different doses of the hexane extract as 
shown in Table 3. The life span of treated mice was also 
not significantly different (p>0.05) from that of 
untreated group which had a mean survival time (MST) 
of 7.8 days.   
The chloroform extract at 100 and 250 mg/kg/day also 
exhibited no curative properties. However, the group of 
mice treated with 500 mg/kg/day of the chloroform 
extract had an MST of 12.3 days. This was significantly 
different (P<0.05) from that of the untreated group (7.8 
days) but still incomparable to the group treated with 
chloroquine which had a MST of 21days.  
3.4 Acute Toxicity Testing and LD50 Determination  
There was no mortality observed within 48 hours for 
mice that received hexane extract as shown in Table 4. 
However, physical signs such as decreased motor 
activity, respiration and feeding, as well as closure of 
eyes were observed.  
The chloroform extract at 5000 and 2811 mg/kg 
produced 60% and 40% mortality, respectively, within 
48 hours. Oral LD50 of the extract was calculated to be 
4166.7 mg/kg. 
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4 Discussion and Conclusion 
Two extracts were tested at 3 different dose levels for 
their in vivo antimalarial properties and also for their 
acute toxicity in mice.  
The chloroform extract at 500 mg/kg/day exhibited 
promising antimalarial activity in both suppressive and 
prophylactic tests. In the curative test, the same dose 
level was associated with an MST that was significantly 
longer than that of the untreated group though 
incomparable to that of chloroquine. The hexane extract 
at 500mg/kg/day had moderate to low suppressive and 
prophylactic properties. In the curative test life span of 
mice was also not significantly different from that of 
untreated group. This lower activity may probably be 
due to the fact that hexane extract mainly consists of 
fats and oils that are often not biologically active 
(Houghton and Raman, 1998). 
The chloroform extract displayed some mild oral acute 
toxicity as shown in Table 4. Coumarins like chalepin 
isolated from C. anisata are reported to be toxic with an 
intraperitoneal LD50 of 100 mg/kg in rats (Emerole et al, 
1981). Coumarins are also reported to be mutagenic 
(Uwaifo, 1984) while carbazole alkaloids, the major 
constituents of C. anisata, are reported to be cytotoxic 
(Ito et al, 2009; Ito et al, 2000). These compounds may 
have contributed to the observed oral mild acute 
toxicity.  
The results of this study indicate that the chloroform 
extract of the C. anisata stem bark possesses 
antimalarial activity. Further studies are required to 
determine if the antimalarial activity of C. anisata is 
attributable to the alkaloid and coumarin constituents. 
Meanwhile, the results partly corroborate claims made 
in traditional medicine of the antimalarial efficacy of 
this plant.   
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